Foralumab is an antibody being developed by Tiziana Life Sciences that's designed to block CD3, a protein on the surface of immune T-cells.| Alzheimer's News Today
Most nonactive SPMS patients who took foralumab nasal spray for at least six months saw a decrease in microglial activity in their brains.| Multiple Sclerosis News Today